PDZRN4
Summary:
Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
---|---|---|---|---|---|
PDZ domain containing ring finger 4 | MIM:609730 | Ensembl:ENSG00000165966 | HGNC:HGNC:30552 | PA134974780 | 12q12 |
GO terms in PDZRN4
Term Type | Evidence Type | GO Term ID | GO Des. |
---|---|---|---|
MF | IEA | GO:0046872 | metal ion binding |
MF | IBA | GO:0061630 | ubiquitin protein ligase activity |
BP | IBA | GO:0016567 | protein ubiquitination |
Gene expression in normal tissue: PDZRN4
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in PDZRN4
Database | Pathway ID | Pathway Des. |
---|
Gene-Drug: Aster Plot
Drug ID | Drug Name | Model Num. |
---|---|---|
iGMDRD375 | GW-405833 | 3 |
iGMDRD394 | BX-795 | 1 |
iGMDRD280 | CYTOCHALASIN B | 5 |
iGMDRD61 | Kinetin riboside | 2 |
iGMDRD201 | SKI II | 2 |
iGMDRD494 | Neopeltolide | 2 |
iGMDRD781 | Sirolimus | 2 |
iGMDRD484 | Pluripotin | 5 |
iGMDRD779 | PRL-3 Inhibitor I | 6 |
iGMDRD420 | Leucascandrolide A | 3 |
iGMDRD23 | Gossypol | 5 |
iGMDRD60 | Quinoclamine | 3 |
iGMDRD369 | TGX-115 | 1 |
iGMDRD888 | Compound 44 | 1 |
iGMDRD780 | PP-30 | 1 |
iGMDRD887 | Compound 23 citrate | 2 |
iGMDRD226 | ML006 | 2 |
iGMDRD318 | PAC-1 | 5 |
iGMDRD207 | Capsaicin | 3 |
iGMDRD782 | DC-45-A2 | 2 |
iGMDRD474 | Avrainvillamide | 1 |
iGMDRD177 | Teniposide | 4 |
iGMDRD351 | GW843682X | 2 |
iGMDRD499 | PDMP | 1 |
iGMDRD47 | ZM336372 | 1 |
iGMDRD512 | nutlin 3 | 3 |
iGMDRD300 | Tozasertib | 4 |
iGMDRD886 | Compound 1541A | 2 |
iGMDRD329 | Merck60 | 2 |
iGMDRD269 | Purmorphamine | 1 |
iGMDRD414 | MST-312 | 5 |
iGMDRD882 | CIL41 | 2 |
iGMDRD77 | Itraconazole | 2 |
iGMDRD231 | Importazole | 2 |
iGMDRD221 | Tamoxifen | 2 |
iGMDRD289 | Parthenolide | 7 |
iGMDRD705 | Nakiterpiosin | 4 |
iGMDRD105 | Triptolide | 1 |
iGMDRD434 | BMS-536924 | 2 |
iGMDRD202 | Curcumin | 3 |
iGMDRD271 | Brefeldin A | 2 |
iGMDRD121 | GMX1778 | 4 |
Gene in drug-gene network: Network Plot
Gene-drug targets distribution
Gene Structure: PDB
Models in PDZRN4